WuXi Biologics and Fresenius strike major deal for up to 37 biosimilars over the next decade

WuXi Biologics and German drugmaker Fresenius have agreed to collaborate on the development and manufacturing of up to 37 biosimilar medicines over the next ten years.

The agreement is described as one of the largest biosimilar deals ever signed, reflecting the growing demand for lower‑cost alternatives to biologic therapies as patents expire.

Both companies see the partnership as a way to capitalize on what industry observers call a “golden decade” for biosimilars, with WuXi providing its large‑scale production capacity and Fresenius contributing its market reach.

The deal positions the two firms to compete more aggressively in the global biosimilar market and could accelerate patient access to affordable treatments.